Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours

dc.creatorVargas, PA
dc.creatorCheng, Y
dc.creatorBarrett, AW
dc.creatorCraig, GT
dc.creatorSpeight, PM
dc.date2008
dc.dateMAY
dc.date2014-11-18T03:45:26Z
dc.date2015-11-26T16:50:41Z
dc.date2014-11-18T03:45:26Z
dc.date2015-11-26T16:50:41Z
dc.date.accessioned2018-03-28T23:37:27Z
dc.date.available2018-03-28T23:37:27Z
dc.identifierJournal Of Oral Pathology & Medicine. Blackwell Publishing, v. 37, n. 5, n. 309, n. 318, 2008.
dc.identifier0904-2512
dc.identifierWOS:000254953400007
dc.identifier10.1111/j.1600-0714.2007.00631.x
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/66483
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/66483
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/66483
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1275790
dc.descriptionBACKGROUND: Recent studies have proposed that minichromosome maintenance (Mcm) proteins may be sensitive proliferation markers and may serve as novel biomarkers for prognostication and diagnosis of various pre-malignant and malignant lesions. The aims of this study were to determine the expression of Mcm-2, Ki-67 and geminin in salivary gland (SG) tumours, and to evaluate their usefulness for diagnosis or for prediction of tumour behaviour. METHODS: Tissue from 62 SG tumours was assembled in tissue microarray format. There were 13 adenoid cystic carcinomas (ACC), 10 carcinoma ex pleomorphic adenomas (CEPA), 10 mucoepidermoid carcinomas (MEC), 10 polymorphous low-grade adenocarcinomas (PLGA), 10 pleomorphic adenomas (PA) and nine acinic cell carcinomas (AcCC). Clinicopathological data were collected retrospectively and immunohistochemical analyses of Mcm-2, Ki-67 and geminin were performed on all lesions. Labelling index (LI) for each marker was determined by counting the percentage of positive cells in six random fields from three arrays per case. RESULTS: Mcm-2 expression was higher than Ki-67 and geminin in all tumours studied. Mcm-2 LI was higher in ACC (28.2 +/- 19.2%) than in CEPA, AcCC, MEC, PA and PLGA (5.3 +/- 4.1%, P = 0.001). Mcm-2 LI was higher in CEPA (20.4 +/- 5.0%) than in PA (6.9 +/- 5.0%, P = 0.001). LI did not correlate to tumour grade or outcome for any of the markers or tumour types. CONCLUSIONS: The findings suggest that Mcm-2 may be a sensitive proliferation marker in SG tumours and may be useful for differential diagnosis between PA and CEPA, and ACC and PLGA. Further studies are warranted to assess the value of Mcm-2 as a predictor of recurrence and survival.
dc.description37
dc.description5
dc.description309
dc.description318
dc.languageen
dc.publisherBlackwell Publishing
dc.publisherOxford
dc.publisherInglaterra
dc.relationJournal Of Oral Pathology & Medicine
dc.relationJ. Oral Pathol. Med.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectgeminin
dc.subjectimmunohistochemistry
dc.subjectKi-67
dc.subjectMcm-2
dc.subjectsalivary gland tumours
dc.subjecttissue microarray
dc.subjectMinichromosome Maintenance Protein-2
dc.subjectMonoclonal-antibody Ki-67
dc.subjectAdenoid Cystic Carcinoma
dc.subjectLow-grade Adenocarcinoma
dc.subjectCell-cycle
dc.subjectNuclear Antigen
dc.subjectDna-replication
dc.subjectBreast-cancer
dc.subjectMarkers
dc.subjectProliferation
dc.titleExpression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución